Replies to post #447489 on Anavex Life Sciences Corp (AVXL)

[longtermbeliever]

GREAT THANK YOU FALCONER66A.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

[Doc328]

Anavex has no say whatsoever over who gets to read it, or what appears in it. What appears is up to the authors and the journal editors, solely --- after the initial review and approval of the peer review experts.

Anavex has a huge say over the article. They sponsored the study and have a right of authorship. No clinician involved in the study can publish the data (owned by ANavex) without permission from Anavex. Conventionally, companies have an academician be the corresponding author (as Hampel was at the time of authorship for the 2a). The editors play a large role in either accepting or refusing an article. They, along with reviewers may suggest changes (or even mandate them as being necessary for publication) but are not going to write any changes. Copy editors may make some grammatical corrections for readability or rarely succintness but will not modify facts or opinions in an article.

but if they release any of it prematurely the article gets nixed; won't be published. Just gotta wait. That's the way science journals operate.

Not quite (or even close). I'm still surprised posters still think an embargo means companies can't release data when and how they want. Maybe you sleep better at night thinking this is out of Missling's hands Obviously, you can't publish the same article twice or key parts of an article twice - this has a lot more to do with copyrights than it does with data. No journal will ever prevent a company from releasing data before publication as long as it is in a different format and as long as the article is still somewhat novel. Just look at the 2a paper. A sizeable percent of the data, but not all, had been released in different format before the paper. The most typical path of important clinical data is: TLD PR, then presentation at a conference in additional detail, then publication in much more detail and with description of methods. Many top tier journals like NEJM will not publish (or even review) a clinical trial without also being able to publish the protocol and SAP in supplementary form. If Missling does not want the SAP to come out (and for legal reasons he may not), you won't see a top notch publication